Tredje AP fonden Sells 1,003 Shares of Humana Inc (NYSE:HUM)

Tredje AP fonden reduced its stake in Humana Inc (NYSE:HUM) by 9.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,852 shares of the insurance provider’s stock after selling 1,003 shares during the period. Tredje AP fonden’s holdings in Humana were worth $3,072,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Humana by 34.2% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,904 shares of the insurance provider’s stock valued at $2,168,000 after buying an additional 1,760 shares during the period. AGF Investments Inc. bought a new stake in shares of Humana in the first quarter valued at approximately $906,000. United Asset Strategies Inc. bought a new stake in shares of Humana in the first quarter valued at approximately $421,000. Nvwm LLC raised its position in Humana by 2.2% during the first quarter. Nvwm LLC now owns 2,583 shares of the insurance provider’s stock valued at $813,000 after purchasing an additional 56 shares in the last quarter. Finally, Commerce Bank raised its position in Humana by 9.9% during the first quarter. Commerce Bank now owns 5,769 shares of the insurance provider’s stock valued at $1,812,000 after purchasing an additional 522 shares in the last quarter. Institutional investors and hedge funds own 93.22% of the company’s stock.

Shares of NYSE:HUM traded down $0.84 during trading on Friday, hitting $394.43. 415,854 shares of the company were exchanged, compared to its average volume of 962,079. The business’s 50 day moving average is $361.93 and its 200-day moving average is $345.82. The company has a market capitalization of $52.26 billion, a P/E ratio of 20.25, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.49. Humana Inc has a 1-year low of $208.25 and a 1-year high of $412.70.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, topping the consensus estimate of $4.84 by $0.56. Humana had a net margin of 3.86% and a return on equity of 21.02%. The company had revenue of $18.94 billion for the quarter, compared to analysts’ expectations of $18.49 billion. During the same quarter in the previous year, the firm posted $4.48 earnings per share. Humana’s revenue for the quarter was up 17.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana Inc will post 18.55 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.625 dividend. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.50 annualized dividend and a dividend yield of 0.63%. Humana’s dividend payout ratio is 13.99%.

In related news, Director David A. Jr/Ky Jones sold 5,800 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $256.19, for a total value of $1,485,902.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.42% of the company’s stock.

HUM has been the subject of several research analyst reports. SunTrust Banks boosted their price objective on shares of Humana from $400.00 to $440.00 and gave the company a “hold” rating in a research report on Thursday. Cantor Fitzgerald boosted their price objective on shares of Humana from $345.00 to $400.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Oppenheimer boosted their price objective on shares of Humana from $400.00 to $425.00 and gave the company an “outperform” rating in a research report on Thursday, April 30th. Royal Bank of Canada restated a “hold” rating and set a $370.00 price objective on shares of Humana in a research report on Wednesday, February 19th. Finally, CSFB boosted their price objective on shares of Humana from $400.00 to $423.00 and gave the company an “outperform” rating in a research report on Thursday, April 30th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $405.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: What causes a recession?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.